Fig. 1

Flowchart for the identification of the mutation panel. Mutation data for coding sequences (CDSs) in TCGA from 486 patients was used to develop a CDS mutation panel for estimating the tumour mutation burden. The performance of the CDS mutation panel was validated in two datasets with data on progression-free survival for patients treated with immune checkpoint inhibitors